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Cell Therapy: Replacement
Lawrence R. Wechsler, MD; Douglas Kondziolka, MD
Not long ago, the ability of the brain to restore functionthrough regeneration of neural elements was thoughtto be nonexistent. It is now known that not only does
some regenerative capacity exist, but implanted cells can
integrate into the host brain, survive, and reverse neurological
deficits. Neural stem cells, fetal transplants, immortalized cell
lines, and bone marrow stromal cells show promise in
experimental models of neurological disease including stroke.
Although it is clear that transplanted cells function, the
mechanism by which neurological deficits might improve is
less certain. Transplanted cells may preserve existing host
cells and connections through secretion of trophic factors;
establish local connections that enhance synaptic activity;
provide a bridge for host axonal regeneration; or actually
replace cellular elements. Several observations from animal
and human studies of cell therapy support the possibility that
transplanted cells exert at least some of their effect through
cellular replacement.
In the early stages of brain development, implanting neural
stem cells leads to replacement of multiple cellular elements
including neurons and glia.1 Thus, the potential for cell
replacement exists, but whether it persists into adulthood is
uncertain. Models of Parkinson’s disease (PD) provide the
most direct support for cell replacement as an important
effect of cell therapy. Fetal ventral mesencephalic neurons
grafted into the striatum in animal models of PD restore
dopamine levels and improve function.2 Similar grafts outside
the striatum fail to achieve clinical benefit. In humans, such
fetal grafts produce clinical benefit3 that accrues gradually
rather than immediately, suggesting an accumulation of
synaptic connections that eventually results in sufficient
dopaminergic transmission to improve neurological deficits.
Autopsy findings in patients receiving fetal grafts demon-
strate implanted cell survival as well as axon growth and
synaptic connections4. Additional support comes from
positron-emission tomography studies showing a correlation
between clinical improvement and increased uptake of
[18F]fluorodopa in the striatum. This favors the concept that
the response to grafting is mediated by direct activity of the
transplanted cells replacing the function of the degenerating
dopaminergic cells of the host nigro-striatal pathway.
The challenge of cell replacement for treatment of stroke is
in some ways similar to that for PD but in other ways is very
different. Like PD, the injury is focal but the neuronal loss
typically involves many more cell types and neurotransmit-
ters. Neural pathways are more complex, and the likelihood
of implanted cells forming appropriately directed connections
necessary to restore function seems remote, unless guided by
the host brain. Despite the potential pitfalls, treatment of focal
ischemia in animals has demonstrated promising results. Fetal
cortical grafts placed in adult neocortex following ischemia
make connections with host neurons including cortex, thala-
mus, and subcortical nuclei.5 Behavioral improvement occurs
in response to these grafts when animals are exposed to an
enriched environment. Neuronal cells derived from a human
teratocarcinoma cell line (NT2 cells) implanted into the
striatum following infarction survive and integrate into the
host brain, growing axons and making synaptic connections.6
Neurological deficits due to stroke are reversed by implanta-
tion.7 The clinical benefit occurs only when a critical number
of cells are transplanted, ensuring adequate cell survival. The
fact that response depends on the number of cells transplanted
suggests the benefit may be mediated by cell replacement.
Extrapolating the results of cell implantation in animal
models of stroke to humans is problematic, particularly
because of the relative lack of adequate primate stroke
models. Unlike PD, in which the motor manifestations of
striatal lesions mimic the human disease, deficits in animals
due to ischemia are more difficult to compare with human
stroke. The first human trial of cell therapy for stroke
included 12 patients treated with LBS neurons derived from
a teratocarcinoma cell line.8 This trial was not designed to
examine efficacy, but improvement in some patients on the
European Stroke Scale scores and NIHSS scores was ob-
served. As in PD, positron-emission tomography studies
showed increased metabolic activity in the area of the grafts
in several patients 6 and 12 months after implantation.9 The
results of an autopsy in one patient 18 months after implan-
tation documented survival of transplanted neuronal cells.10
Taken together, these data support the concept that activity of
implanted cells is responsible for clinical changes. Further
studies are needed to more precisely determine the role of cell
replacement—whether the implanted cells form new neural
pathways, make local connections, or work by neurohumoral
mechanisms.
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In the end it is likely that multiple mechanisms contribute
to the effect of cell transplantation. Trophic factors may be
necessary to promote survival and integration of grafted cells.
Implanted cells may also induce host responses that both
promote function of the graft and directly contribute to
neurological recovery. Although the prospect of replacing
brain damaged by ischemia appears daunting, initial experi-
ence in this field suggests it is not only possible but plausible.
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Stem Cells: Do They Replace or Stimulate?
David Howells, BSc(Hons), PhD
In 2002, more than 6000 articles were published on stemcell biology. Many argued that the importance of thesecells lies in their potential to provide transplants for
treatment of diseases such as stroke, Parkinson’s disease, and
spinal cord injury. The fervor is such that human embryos
have been cloned, despite substantial ethical concerns, with
the justification that “therapeutic cloning” will provide the
stem cells needed for widespread transplantation for incur-
able diseases.
Stem cells prepared from human bone marrow,1 neuronal
progenitor cells from adult rat dentate gyrus,2 and embryonic
human forebrain3 all engraft successfully within the brain
parenchyma and can differentiate into neurons.2 Surprisingly
these engrafted cells can migrate to join existing neural stem
cell migratory pathways,1,3 and when the brain is injured,
migration is redirected specifically to the site of damage.4
After stroke in rodents, stem cells derived from bone
marrow induce functional recovery measured by rotarod,
adhesive-removal, and modified neurologic severity score
tests when implanted into striatum5 or cortex6 or after
intra-arterial infusion.7 Importantly, these improvements
were noted when implantation occurred up to 14 days7 after
stroke, were enhanced by brain-derived neurotrophic factor,8
and were achieved when very few implanted cells expressed
neural markers9 and still retained a relatively undifferentiated
morphology.6 Importantly, despite marked functional im-
provements, the infarcts do not get smaller.5 This latter
observation would appear to exclude the possibility that the
stem cells secrete neuroprotective factors that enhance sur-
vival of neurons susceptible to infarction.
These observations have led to speculation that increased
host plasticity rather than differentiation and integration of
new neurons must account for the observed improvements.6,9
The idea of host CNS regenerative responses is not new,
but their form and functional significance have remained
contentious. At the start of the 20th century, Ramon y Cajal
was among the first to study neurite sprouting after brain and
spinal injury but decided that these host responses were
aborted attempts at reconstruction of severed pathways with
little functional significance. This perception changed little
until the late 1960s, when Raisman observed that axons in
neighboring undamaged pathways could send out additional
axonal branches or “collateral sprouts” to reinnervate the
septum after it had been denervated.
Interestingly, such observations of host plasticity played a
key role in promoting transplantation as a treatment for
neurological disease, and today intrastriatal implants of fetal
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dopaminergic neurons are viewed by many as a moderately
successful way of alleviating the symptoms of Parkinson’s
disease. However, as in stem cell transplants for stroke, there
is also a body of evidence to suggest that host responses may
play a significant role in the functional recovery observed
after dopaminergic implants.
Autologous adrenal medullary implants in particular were
enthusiastically performed in several countries. However, they
have been found to be of only mild benefit in less than half of the
transplanted patients, and even in patients who improved,
subsequent autopsies consistently demonstrated little or no
survival of adrenal grafts. The feature that seemed to best
correlate with the clinical improvement in animals and man was
the presence of peri-wound host dopaminergic sprouting,10
which has been shown to be a consequence of surgical injury to
the striatum and dependent on neurotrophins and growth factors
supplied by activated microglia and macrophages.11
Is enhancement of such host axonal sprouting responsible for
stem cell–induced recovery in animal models of stroke?
It would seem prudent to conclude that although stem cell
grafts to treat stroke are in their infancy, they do appear to be
able to foster functional improvement in animal models of
stroke. However, their mechanism of action is far from clear.
Perhaps our greatest challenge will be to establish the propor-
tional significance of all mechanisms and fine-tune our treat-
ments to provide the greatest benefit for the victims of stroke.
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Stem Cell Transplantation for Stroke:
Does It Work, and If So, How?
Marc Fisher, MD
An increasing number of experiments in animal strokemodels demonstrated that a variety of different typesof stem cells implanted directly into the central
nervous system or delivered systemically beneficially affect
functional outcome. In these experiments, stem cells are
given days to weeks after stroke onset without affecting
infarct size. How the various types of stem cells induce their
beneficial effects on functional outcome remains a matter of
speculation, but Howells and Wechsler/Kondziolka suggest a
number of intriguing possibilities revolving around direct
functional activities of the implanted stem cells versus stim-
ulation of intrinsic host recovery mechanisms. As these
authors suggest, it is likely that both effects may occur and
different mechanisms may predominate with individual sub-
types of stem cells or at different times after stroke onset.
Much further experimental work will be needed to dissect the
precise mechanisms of stem cell effects on neurological/func-
tional recovery after stroke. The utility of stem cell treatment for
stroke will need to be explored in primate stroke models and
then in carefully designed initial and advanced clinical trials. The
initial small animal experiments provide reasons for excitement,
but as has been learned in other neurological disorders, there are
many potential pitfalls. All stroke specialists and stroke patients
need to pay close attention to this field as it unfolds with both
cautious optimism and healthy skeptical reserve.
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